ClinicalTrials.gg
RecruitingNCT07734493Updated Sep 17, 2026

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

A Phase 1 interventional study of LTX-001 once daily and Placebo in Schizophrenia, sponsored by Leal Therapeutics, Inc. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Leal Therapeutics, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Planned enrollment
547th of 1,320
90 · median 66
Started
2026
with 49 others
Phase 1
196 of 1,466
9 open now
Primary completion
2027-03
later than 49 of 165 live
Registered
1,450th of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 547th largest by planned enrollment of the 1,320 interventional ones that give a count, is one of 50 that started in 2026, is one of 196 in phase 1, reaches primary completion later than 49 of the 165 other live ones, and was the 1,450th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

142 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are:

  • how does the amount of the study drug in the body change over time (pharmacokinetics)
  • how does the study drug affect the symptoms of schizophrenia
  • how do certain markers in the blood change after administration of LTX-001 (pharmacodynamics)

Researchers will compare different dose levels of LTX-001 to an inactive product (placebo) to see what differences there are between the two treatments.

After successfully screening for the study, participants will stay in a research unit for about five weeks and return one week later for a follow-up visit.

Read the detailed description

After providing informed consent, eligible participants will be asked to visit the study site 3 times and stay overnight for 35 nights (up to 49 nights if up to 14 days of antipsychotic washout is applicable). Procedures will include:

  • A review of medical history and medications
  • Physical exams, including a neurologic (nervous system) assessment
  • Electrocardiograms (a measure of the heart's electrical activity)
  • Blood and urine collection
  • Psychiatric assessments including the Mini International Neuropsychiatric Exam (MINI), the Brief Assessment of Cognition in Schizophrenia (BACS), and the Positive and Negative Syndrome Scale (PANSS)
  • Overall assessment of status via the Clinical Global Impression Scale - Severity (CGI-S)
  • Assessment of extrapyramidal symptoms (EPS) as assessed by the Modified Simpson-Angus Scale (M-SAS), the Abnormal Involuntary Movement Scale (AIMS) and the Barnes Akathisia Rating scale (BARS)
  • Assessment of suicidality risk via the Columbia Suicidality Severity Rating Scale (C-SSRS)
  • Quantitative electroencephalography (qEEG) assessments
  • Ophthalmologic examinations
  • Administration of the study drug (or placebo) by mouth
03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 17.5 and \< 38.0 kg/m2 and a total body weight > 50.0 kg (110 lbs)
  • Primary diagnosis of schizophrenia per the , 5th Edition (DSM-5-TR)
  • Experiencing an acute exacerbation or relapse of symptoms, with onset less than 2 months prior to screening for the study
  • PANSS total score ≥ 80 at the time of screening for the study
  • Not currently on antipsychotic medication, or is willing to discontinue all prohibited psychotropic medications prior to and during the trial period
  • Sexually active adults must be willing to use an acceptable method throughout the study

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any abnormal finding at physical examination
  • History of treatment resistance (e.g., failure to respond to ≥ 2 adequate antipsychotic trials) or failure to respond to use of clozapine
  • Current diagnosis other than schizophrenia
  • Pregnant or lactating female
  • Substance use disorder within 1 year prior to screening or recreational use of drugs within 3 months prior to screening
  • Moderate to severe alcohol use disorder as per DSM-5-TR within the past year or excessive use of alcohol within 12 months prior to screening
  • Positive testing for (HIV)-1 and -2 antibody, surface antigen (HBsAg), or virus (HCV) antibody at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    LTX-001 once daily

    LTX-001

    Drug: LTX-001 once daily

  • Experimental
    LTX-001 twice daily

    LTX-001

    Drug: LTX-001 twice daily

Interventions

  • DrugLTX-001 once daily

    LTX-001 40 mg and 60 mg administered as oral suspension

  • DrugPlacebo

    Oral suspension without LTX-001

  • DrugLTX-001 twice daily

    LTX-001 30 mg and 60 mg administered as oral suspension

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability - Adverse Events

    Incidence and severity of treatment-emergent adverse events (TEAEs), and treatment-emergent serious adverse events (TESAEs).

    Time frame: Screening through Day 42

  2. Safety and Tolerability - Clinical Laboratory Tests

    Clinical laboratory tests (including serum chemistry, hematology, urinalysis)

    Time frame: Screening through Day 42

  3. Safety and Tolerability - Electrocardiograms (ECG)

    ECGs will measure heart rate (HR), QRS complex and QT, QTcF, and PR intervals

    Time frame: Screening through Day 42

  4. Safety and Tolerability - Physical and Neurological Exams

    Physical and neurological exams will be performed periodically to ensure participant safety.

    Time frame: Screening through Day 42

  5. Safety and Tolerability - Suicidality

    Suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: Screening through Day 42

  6. Safety and Tolerability - Extrapyramidal Symptoms

    Extrapyramidal symptoms (EPS) as assessed by the Modified Simpson-Angus Scale (M-SAS), the Abnormal Involuntary Movement Scale (AIMS) and the Barnes Akathisia Rating scale (BARS)

    Time frame: Screening through Day 42

  7. Vital signs - blood pressure

    Vital signs will be collected, including blood pressure (mm Hg)

    Time frame: Screening through Day 42

  8. Vital Signs - heart rate

    Vital signs will be collected, including heart rate (beats per minute)

    Time frame: Screening through Day 42

  9. Vital Signs - respiratory rate

    Vital signs will be collected, including respiratory rate (breaths per minute)

    Time frame: Screening through Day 42

  10. Vital Signs - body temperature

    Vital signs will be collected, including body temperature (°C or °F)

    Time frame: Screening through Day 42

  11. Vital Signs - total body weight

    Vital signs will be collected, including total body weight (kilograms)

    Time frame: Screening through Day 42

  12. Vital Signs - height

    Vital signs will be collected, including height (centimeters)

    Time frame: Screening through Day 42

  13. Vital Signs - Body Mass Index (BMI)

    Body Mass Index (BMI) will be calculated using the values of total body weight and height, with the formula BMI = weight in kg/(height in cm)\^2.

    Time frame: Screening through Day 42

  14. Ocular evaluation - Best Corrected Visual Acuity (BCVA)

    Ocular evaluations, including Best Corrected Visual Acuity (BCVA) will be performed

    Time frame: Screening through Day 42

  15. Ocular evaluation - dilated Color Fundus Photography (CFP)

    Ocular evaluations, including dilated Color Fundus Photography (CFP) will be performed

    Time frame: Screening through Day 42

  16. Ocular evaluation - Fundus Autofluorescence (FAF)

    Ocular evaluations, including Fundus Autofluorescence (FAF) will be performed

    Time frame: Screening through Day 42

  17. Ocular evaluation - dilated Optical Coherence Tomography (OCT)

    Ocular evaluations, including dilated Optical Coherence Tomography (OCT) of the macula and optic nerve will be performed

    Time frame: Screening through Day 42

  18. Ocular evaluation - slit lamp examination

    Ocular evaluations, including slit lamp examination with measurement of intraocular pressure (IOP) will be performed

    Time frame: Screening through Day 42

Secondary outcomes

  1. Pharmacokinetics of LTX-001 - Single Dose

    Single-dose plasma PK parameters (Days 1 and 8) will be measured

    Time frame: Days 1 and 8

  2. Pharmacokinetics of LTX-001 - Multiple Dose

    Multiple-dose plasma PK parameters (Day 35) will be measured.

    Time frame: Days 8 and 35

Other outcomes

  1. Efficacy of LTX-001 - PANSS

    Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score and subscale scores

    Time frame: Screening through Day 37

  2. Efficacy of LTX-001 - Marder factors of PANSS

    Change from baseline in the Marder factors of PANSS.

    Time frame: Screening through Day 37

  3. Efficacy of LTX-001 - BACS

    Change from baseline in the Brief Assessment of Cognition in Schizophrenia (BACS)

    Time frame: Screening through Day 37

  4. Efficacy of LTX-001 - CGI-S

    Change from baseline in Clinical Global Impression Scale-Severity (CGI-S) score

    Time frame: Screening through Day 37

  5. Pharmacodynamics of LTX-001 - plasma glutamate and glutamine

    Change from baseline in plasma glutamine (Gln) and glutamate (Glu) concentrations and Gln/Glu ratio. In addition, using glutamine change from baseline data, the individual AUEC0-4, AUEC0-12 and AUEC0-24 will be presented for each patient, by treatment group on Days 1, 8, and 35

    Time frame: Day 1 through Day 36

  6. Efficacy of LTX-001 - Quantitative electroencephalography (qEEG)

    Change from baseline in resting-state qEEG parameters (alpha, beta, gamma, delta, and theta) on Days -1, 3, and 35.

    Time frame: Day -1, Day 3 and Day 35

  7. Pharmacodynamics of LTX-001 - Metabolite Profiling

    Metabolite profiling and identification in pooled plasma samples of selected days from LTX-001 once and twice daily groups

    Time frame: Day 1 through Day 36

07

Study locations

10 of 10 sites recruiting
  • Pillar Clinical Research, LLC
    Little Rock, Arkansas 72204, United States
    Recruiting
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
    Recruiting
    • Study Recruiter · Contact(714)-891-0971
    • David Walling, PhD · Principal investigator
  • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
    Recruiting
  • Behavioral Clinical Research, Inc.
    Hollywood, Florida 33021, United States
    Recruiting
  • CenExel Hollywood FL
    Hollywood, Florida 33024, United States
    Recruiting
    • Edwin A Gomez · Contact954-990-7649
    • Edwin A Gomez, MD · Principal investigator
  • Innovative Clinical Research, Inc.
    Miami Lakes, Florida 33016, United States
    Recruiting
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
    Recruiting
  • CBH Health LLC., dba CenExel Gaithersburg MD
    Gaithersburg, Maryland 20877, United States
    Recruiting
    • Elia Acevedo-Diaz · Contact301-251-4702
    • Elia Acevedo-Diaz, MD · Principal investigator
  • Hassman Research Institute, LLC
    Marlton, New Jersey 08053, United States
    Recruiting
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 7 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 29, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734493
Lead sponsor
Leal Therapeutics, Inc
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Aug 3, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Clinical Trials Information Medical Monitor
Contact
clinical.trials@lealtx.com
267-503-4800
Study Director Medical Monitor
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion